Physician profile
Samer Kassar
NPI 1902839525
$77,936.75
in general payments reported to CMS, 2019-2025
87 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,042 · 2020: $3,258 · 2021: $12K · 2022: $7,928 · 2023: $8,395 · 2024: $17K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $14K · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,731.25 |
| Food and Beverage | $14,242.05 |
| Education | $242.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49,636.34 | 2021-2025 | |
| Biogen, INC. | $4,586.54 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $1,346.92 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Allergan, INC. | $1,321.89 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $1,263.20 | 2019-2025 | |
| Lilly USA, LLC | $1,234.76 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Banner Life Sciences, LLC | $1,174.11 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $991.58 | 2019-2025 | Ultomiris, Soliris |
| Catalyst Pharmaceuticals, INC. | $981.68 | 2023-2025 | Fycompa |
| Teva Pharmaceuticals USA, INC. | $760.38 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Eisai INC. | $710.83 | 2019-2025 | |
| Sk Life Science, INC. | $704.35 | 2020-2025 | Xcopri |
| Livanova USA, INC. | $645.06 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Mdd US Operations, LLC | $626.11 | 2019-2025 | Apokyn, Apokyn |
| Jazz Pharmaceuticals INC. | $610.74 | 2021-2025 |
Show all 87 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Kassar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.